Product image of Mefoxil 2 G/Vial (Cefoxitin Sodium) supplied by GNH India

Mefoxil 2 G/Vial

Active Ingredient:
Cefoxitin Sodium
Origin:
EU

Mefoxil 2 G/Vial (Cefoxitin Sodium)

Cefoxitin sodium, the active ingredient in Mefoxil, is a second‑generation cephalosporin presented as a 2 g injectable solution (vial) for intravenous and intramuscular use. It treats a range of bacterial infections in adult and pediatric patients.

GNH India supplies Mefoxil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Vianex S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Cefoxitin sodium is a broad‑spectrum second‑generation cephalosporin used to treat infections caused by susceptible bacteria.

  • Respiratory tract infections: effective for community‑acquired pneumonia and bronchitis.
  • Urinary tract infections: clears uncomplicated cystitis and pyelonephritis.
  • Intra‑abdominal infections: treats peritonitis and postoperative intra‑abdominal sepsis.
  • Gynecologic infections: manages pelvic inflammatory disease and postoperative uterine infections.
  • Skin and soft tissue infections: resolves cellulitis, abscesses and wound infections.

How It Works

  • Cefoxitin sodium binds to penicillin‑binding proteins on the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial lysis, particularly against gram‑positive and many gram‑negative organisms.

Side Effects

Adverse reactions may occur with any injectable antibiotic. Monitoring for both common and serious events is recommended.

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the administration site.
  • Phlebitis: inflammation of the vein used for infusion.
  • Diarrhea: loose stools, often self‑limiting.
  • Nausea: transient feeling of queasiness.
  • Rash: mild erythematous skin eruption.
  • Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects

  • Anaphylaxis: severe, potentially life‑threatening allergic reaction.
  • Clostridioides difficile‑associated diarrhea: severe colitis following antibiotic disruption of gut flora.
  • Stevens‑Johnson syndrome: rare mucocutaneous blistering disorder.
  • Hemolytic anemia: immune‑mediated destruction of red blood cells.
  • Renal impairment: acute kidney injury, especially in patients with pre‑existing dysfunction.
  • Seizures: rare neurotoxic effect, particularly with high doses or renal failure.

Precautions & Warnings

Cefoxitin sodium requires careful assessment before and during therapy.

  • Allergy assessment: verify no history of severe penicillin or cephalosporin hypersensitivity.
  • Renal function monitoring: adjust dosage in patients with impaired kidney function.
  • Hepatic function evaluation: use caution in patients with liver disease.
  • Pregnancy considerations: category B, weigh maternal benefit against potential fetal risk.
  • Contraindication check: avoid in individuals with documented severe cephalosporin allergy.
  • Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Cefoxitin sodium can interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid)

  • Concurrent nephrotoxic agents (e.g., aminoglycosides): may increase risk of renal toxicity.
  • Probenecid: reduces renal clearance of cefoxitin, potentially raising serum levels.
  • Live bacterial vaccines: antibiotic may diminish vaccine effectiveness.

Moderate Interactions (Monitor Closely)

  • Loop diuretics: may enhance nephrotoxic potential.
  • Oral contraceptives: possible reduction in contraceptive efficacy.
  • Warfarin: may cause unpredictable changes in INR, requiring closer monitoring.

Frequently Asked Questions

Mefoxil contains cefoxitin sodium, a second‑generation cephalosporin indicated for a variety of bacterial infections such as community‑acquired pneumonia, urinary tract infections, intra‑abdominal sepsis, gynecologic infections, and skin or soft‑tissue infections caused by susceptible organisms.

Cefoxitin sodium binds to penicillin‑binding proteins on the bacterial cell wall, blocking the cross‑linking of peptidoglycan strands. This inhibition weakens the cell wall, causing osmotic rupture and bacterial cell death, particularly against many gram‑positive and gram‑negative pathogens.

The specific dose of Mefoxil is determined by the prescribing clinician based on the type and severity of infection, patient age, weight, renal function, and local antimicrobial guidelines. Only a qualified healthcare professional should set the dosing regimen.

Cefoxitin sodium is classified as pregnancy category B, indicating no evidence of risk in animal studies and a lack of well‑controlled human data. It may be used during pregnancy when the potential benefit justifies any potential risk. Limited data are available for breastfeeding, so clinical judgment is required.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mefoxil. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Mefoxil (cefoxitin) is a second‑generation cephalosporin offering broader gram‑negative coverage than first‑generation agents while retaining activity against many gram‑positive organisms. Compared with third‑generation cephalosporins, it has less activity against Pseudomonas but a lower risk of inducing certain resistant strains, making it suitable for mixed‑flora infections.

Mefoxil should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain stability and sterility.

Mefoxil is supplied as a sterile injectable solution for intravenous (IV) or intramuscular (IM) administration. The vial is reconstituted with the appropriate diluent as per the prescribing information, and the dose is delivered by a qualified healthcare professional using aseptic technique.

Serious adverse events, though rare, include anaphylactic reactions, Clostridioides difficile‑associated colitis, Stevens‑Johnson syndrome, hemolytic anemia, acute renal impairment, and seizures. Immediate medical attention is required if any of these symptoms develop during therapy.

Mefoxil is contraindicated in patients with a documented severe allergy to cefoxitin, other cephalosporins, or penicillins. It should also be avoided in individuals who have experienced previous severe hypersensitivity reactions to beta‑lactam antibiotics.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cefoxitin Sodium

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT